Xarelto and Brilinta already well represented in US hospital formularies

In the USA, formulary inclusion of the new anticoagulant Xarelto (rivaroxaban) from German drug major Bayer (BAY: DE), and the new antiplatelet Brilinta (ticagrelor) from Anglo-Swedish AstraZeneca (LSE: AZN) is high among surveyed institutions, either on open or restricted formulary access, despite having gained Food and Drug Administration approval only within the past year.

Furthermore, according to the Hospital Formulary Insights: Anti-Thrombotics (US) report from BioTrends, a Decision Resources business, a large proportion of hospitals that have not yet reviewed Xarelto and Brilinta expect them to be added to the hospital formulary after review. Among hospitals that have rivaroxaban on formulary, its being an alternative to warfarin is the primary reason for the drug gaining formulary inclusion.

Eliquis and otamixaban also expected to get formulary inclusion